Titre
Point de vue actuel du traitement des epilepsies: place des nouveaux antiepileptiques? [Current viewpoints in the treatment of epilepsies: role of new antiepileptics?]
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Despland, P. A.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1013-2058
Statut éditorial
Publié
Date de publication
1995-09
Volume
84
Numéro
38
Première page
1036
Dernière page/numéro d’article
41
Notes
English Abstract
Journal Article
Review --- Old month value: Sep 19
Journal Article
Review --- Old month value: Sep 19
Résumé
Although standard anticonvulsants are effective in achieving complete seizure control in the majority of patients, an appreciable proportion (about 20 to 25%) is at least in part resistant to conventional pharmacotherapy. Efficacy of carbamazepine, phenytoin, phenobarbital and valproate is very similar. Should one drug fail because of inadequate efficacy and unacceptable adverse effects, an alternative monotherapy should be used. Surgical treatment is a possible therapeutic option for only some of these patients. The development of newer, more effective drugs, such as vigabatrin, lamotrigine, gabapentin and oxcarbazepine, for monotherapy is desirable. The search for new antiepileptic agents is reasonable in order to reduce the proportion of drug-resistant patients. The choice of conventional or new drugs should include not only expected efficacy and risk of adverse effects, but also pharmacokinetic properties and expense. Consequently, no general rule is appropriate, and each decision and recommendation for treatment should be individualized.
Sujets
PID Serval
serval:BIB_E40CDC6B7278
PMID
Date de création
2008-01-25T10:40:51.586Z
Date de création dans IRIS
2025-05-21T06:24:27Z